Showing 5111-5120 of 7091 results for "".
- Analysis: Proximity to Tanning Facilities Correlates with Increased Melanoma Incidence in New Englandhttps://practicaldermatology.com/news/analysis-proximity-to-tanning-facilities-correlates-with-increased-melanoma-incidence-in-new-england/2473824/Results from a new analysis suggest a correlation between proximity to tanning facilities and higher melanoma inc
- Andrew Weinstein Voted AAD President-Electhttps://practicaldermatology.com/news/Andrew-Weinstein-Voted-AAD-President-Elect/2471798/Andrew H. Weinstein, MD, MPH, FAAD, was voted president-elect of the American Academy of Dermatology (AAD), the organization announced. Dr. Weinstein will be joined by vice president-elect Thomas E. Rohrer, MD, FAAD. Newly elected members of the board of directors are Alina G. Bridges, DO,
- Secukinumab Reduces Erosions in Psoriatic Arthritis Patientshttps://practicaldermatology.com/news/secukinumab-reduces-erosions-in-psoriatic-arthritis-patients/2471713/Secukinumab significantly reduced erosion progression in patients with psoriatic arthritis (PsA), according to findings from a phase 4 randomized, double-blind, placebo-controlled trial. The study evaluated the impact of the I
- Meta-Analysis Validates SLNB Prediction Toolshttps://practicaldermatology.com/news/meta-analysis-validates-slnb-prediction-tools/2471653/A new systematic review and meta-analysis found several externally validated risk prediction models for sentinel lymph node biopsy (SLNB) positivity in melanoma with strong discriminative performance, though significant heterogeneity was observed.
- Interim Analysis: Dupilumab Reduces Itch, Pain in Ichthyosis and EBhttps://practicaldermatology.com/news/Interim-Analysis-Dupilumab-Reduces-Itch-Pain-Ichthyosis-EB/2471652/Dupilumab reduced both itch and pain in congenital ichthyosis and epidermolysis bullosa (EB), with no new safety issues, in an interim analysis presented during the late-breakers sessions at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. Medical student
- PN Therapeutic Pipeline Continues to Show Promisehttps://practicaldermatology.com/news/PN-Therapeutic-Pipeline-Continues-Show-Promise/2471649/The US Food and Drug Administration (FDA) approval last year of nemolizumab for the treatment of adults with prurigo nodularis (PN) was likely only the beginning of a dramatically changing therapeutic landscape for that condition, Sonja Stander, MD, IFAAD, said at the 2025 American Academy of Der
- From AAD: What's New in Acne and Rosacea?https://practicaldermatology.com/news/from-aad-whats-new-in-acne-and-rosacea/2471565/Dermatologists gathered for the Acne and Rosacea session at the 2025 American Academy of Dermatology in Orlando conference were treated to comprehensive updates on two prevalent skin conditions—acne and rosacea—presented by Julie Harper, MD, and Hilary Baldwin, MD,
- Charlotte Dermatology, DOCS Dermatology Group Partner, With PGP as Advisorhttps://practicaldermatology.com/news/Charlotte-Dermatology-DOCS-Dermatology-Group-Partner-With-PGP-Advisor/2471624/Physician Growth Partners (PGP) announced it recently advised Charlotte Dermatology on its partnership with DOCS Dermatology Group (backed by SkyKnight Capital). Founded in 1939, Charlotte Dermatology is one of the longest-standing and most trusted dermatology practices in the Greater Char
- Further Positive Delgocitinib Data Presented at AADhttps://practicaldermatology.com/news/Further-Positive-Delgocitinib-Data-Presented-AAD/2471609/Late-breaking data presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, showcased responses in a subgroup of patients from the DELTA 1 and Delta 2 trials on lebrikizumab for chronic hand eczema. Alongside this presentation, new systemic exposure
- Analysis: Lower PsA Risk Linked to Psoriasis Treatment Target Achievementhttps://practicaldermatology.com/news/lower-psa-risk-linked-to-psoriasis-treatment-target-achievement/2471577/Patients with psoriasis who achieve the National Psoriasis Foundation (NPF) treatment target after starting biologic therapy may experience a reduced risk of developing psoriatic arthritis (PsA), according to findings from the CorEvitas Psoriasis Registry.